CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01859702
NCT01859702Phase 4Completed
CompareCT.gov

Pharmacokinetic Evaluation of Moxifloxacin in Vigadexa® in Aqueous Humor Samples Following Preoperative Antibiotic/Steroid Dosing in Cataract Surgery Patients

Alcon Research·interventional·Posted May 22, 2013·Updated Aug 7, 2013

In Brief

A Phase 4 clinical trial evaluating Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution for Cataract. Completed, enrolled 36 participants.

Detailed Summary

The purpose of this study was to determine the moxifloxacin aqueous penetration when dosing with a combination drug Vigadexa preoperatively in cataract patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCataract
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 22, 2013
Enrollment StartApr 1, 2012
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 13.1 years ago

Interventions

Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solutiondrug